Literature DB >> 23192747

Is There Still a Role for Fibrinolysis in ST-Elevation Myocardial Infarction?

C El Khoury1, F Sibellas, E Bonnefoy.   

Abstract

OPINION STATEMENT: Fibrinolysis had long been the reference treatment in patients with ST-Elevation Myocardial Infarction (STEMI). It was associated with a large reduction in mortality as compared with delayed or no reperfusion in patients managed early, within the first 2 hours from the onset of symptoms. Fibrinolysis also had well-known potential complications: cerebral haemorrhage, especially in patients beyond 75 years, and reinfarction. Primary percutaneous intervention (PCI) has overcome most of these limitations, but at a price: PCI-related delays that can reduce the expected benefit of primary PCI compared with fibrinolysis. That primary PCI is today the treatment of choice in patients with STEMI is no longer discussed. However, fibrinolysis should still maintain a role in the management of acute myocardial infarction (AMI) for three reasons. First, fibrinolysis is no longer a stand-alone treatment. Modern fibrinolytic strategies combine immediate fibrinolysis, loading dose of thienopyridines, and transfer to a PCI hospital for rescue or early PCI within 24 hours. These strategies capitalize on the hub-and-spoke networks that have, or should have, been built everywhere to implement primary PCI. The overall clinical results of these modern fibrinolytic strategies are now similar to those of primary PCI. Second, a substantial number of patients cannot be managed with primary PCI within the reasonable time thresholds set by the guidelines. In the case of long PCI-related delays, patients will benefit from fibrinolysis before or during transfer to a PCI hospital. Third, modern fibrinolytic strategies-immediate fibrinolysis followed by rescue or early PCI-may even offer the best results of all in a subset of patients. Patients of less than 75 years, managed within the first 2 hours and who cannot have immediate PCI, will fare better with a modern fibrinolytic strategy than with primary PCI. Guidelines advocate regional networks between hospitals with and without PCI capabilities, an efficient ambulance service and standardization of AMI management through shared protocols. These regional logistics of care are essential to take full advantage of fibrinolysis strategies. In order to check that these strategies are correctly applied, networks need ongoing registries, as well as benchmarking and quality improvement initiatives.

Entities:  

Year:  2013        PMID: 23192747     DOI: 10.1007/s11936-012-0218-1

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  75 in total

1.  Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis.

Authors:  L J Morrison; P R Verbeek; A C McDonald; B V Sawadsky; D J Cook
Journal:  JAMA       Date:  2000 May 24-31       Impact factor: 56.272

2.  Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol.

Authors:  Henry H Ting; Charanjit S Rihal; Bernard J Gersh; Luis H Haro; Christine M Bjerke; Ryan J Lennon; Choon-Chern Lim; John F Bresnahan; Allan S Jaffe; David R Holmes; Malcolm R Bell
Journal:  Circulation       Date:  2007-08-01       Impact factor: 29.690

3.  Rescue angioplasty or repeat fibrinolysis after failed fibrinolytic therapy for ST-segment myocardial infarction: a meta-analysis of randomized trials.

Authors:  Harindra C Wijeysundera; Ram Vijayaraghavan; Brahmajee K Nallamothu; JoAnne M Foody; Harlan M Krumholz; Christopher O Phillips; Amir Kashani; John J You; Jack V Tu; Dennis T Ko
Journal:  J Am Coll Cardiol       Date:  2007-01-12       Impact factor: 24.094

Review 4.  Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future?

Authors:  Bernard J Gersh; Gregg W Stone; Harvey D White; David R Holmes
Journal:  JAMA       Date:  2005-02-23       Impact factor: 56.272

5.  Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1993-08-05       Impact factor: 91.245

6.  Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.

Authors:  E J Topol
Journal:  Lancet       Date:  2001-06-16       Impact factor: 79.321

7.  Intraluminal thrombus in facilitated versus primary percutaneous coronary intervention: an angiographic substudy of the ASSENT-4 PCI (Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention) trial.

Authors:  Jaroslaw Zalewski; Kris Bogaerts; Walter Desmet; Peter Sinnaeve; Peter Berger; Cindy Grines; Thierry Danays; Paul Armstrong; Frans Van de Werf
Journal:  J Am Coll Cardiol       Date:  2011-05-10       Impact factor: 24.094

8.  Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial.

Authors:  Sanjit S Jolly; Salim Yusuf; John Cairns; Kari Niemelä; Denis Xavier; Petr Widimsky; Andrzej Budaj; Matti Niemelä; Vicent Valentin; Basil S Lewis; Alvaro Avezum; Philippe Gabriel Steg; Sunil V Rao; Peggy Gao; Rizwan Afzal; Campbell D Joyner; Susan Chrolavicius; Shamir R Mehta
Journal:  Lancet       Date:  2011-04-04       Impact factor: 79.321

9.  Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2.

Authors:  J H Gurwitz; J M Gore; R J Goldberg; H V Barron; T Breen; A C Rundle; M A Sloan; W French; W J Rogers
Journal:  Ann Intern Med       Date:  1998-10-15       Impact factor: 25.391

Review 10.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

Authors:  Ellen C Keeley; Judith A Boura; Cindy L Grines
Journal:  Lancet       Date:  2003-01-04       Impact factor: 79.321

View more
  1 in total

Review 1.  Effectiveness of regionalized systems for stroke and myocardial infarction.

Authors:  James P Rhudy; Marie A Bakitas; Kristiina Hyrkäs; Rita A Jablonski-Jaudon; Erica R Pryor; Henry E Wang; Anne W Alexandrov
Journal:  Brain Behav       Date:  2015-09-23       Impact factor: 2.708

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.